25 companies
Quebec
Aramis Biotechnologies is seeking strategic partnerships in plant-based biomanufacturing across human health, animal health, agriculture, and industrial applications. Our objective is to showcase our transient expression platform, manufacturing capabilities, and expertise, while exploring collaboration, co-development, and commercialization opportunities with Korean and international partners.
Ontario
BioBox is actively seeking partnership opportunities with biopharma R&D teams looking to build/scale AI-driven drug discovery systems.
Reconnect with current stakeholders and build additional connections to help the market entry.
Ontario
To increase Canadian biotech visibility among foreign partners, investors, and buyers through global events and promotional outreach. To connect with international delegates and build new partnerships with foreign contacts. To strengthen Canada’s global reputation and raising awareness of its expertise and opportunities in the biotechnology industry.
The CPDC is a radiopharmaceutical company that looks to create new companies based around novel radiopharmaceutical technologies. We are looking for in-licensing, equity investment and collaboration opportunities in therapeutics, diagnostics and enabling technologies.
British Columbia
CereCura Nanotherapeutics is seeking to connect with Korean biotech and pharma partners to explore collaboration opportunities in LNP-mRNA drug delivery for central nervous system diseases, building on our lead program in neuronopathic Gaucher disease and expanding pipeline in Parkinson's and Alzheimer's disease. We are particularly interested in R&D collaboration, co-development, licensing, or strategic partnership discussions with companies advancing CNS-targeted therapeutics or complementary delivery platforms. We also welcome conversations with strategic investors and corporate partners interested in cross-border collaboration in nanomedicine and rare/neurodegenerative disease.
Ontario
Looking for pharmaceutical partners who would be interested in licensing our late stage products in Vitiligo, Acute Contact and Dermatitis and ARDS.
Ontario
Epiloid Biotechnology seeks to introduce its human brain organoid platform to Korean pharmaceutical companies and research institutions as a differentiated preclinical CNS drug screening solution. Our goal is to establish drug screening service agreements and research collaborations that leverage Korea's strong neuropharmacology pipeline and Epiloid's proprietary organoid technology. We are specifically interested in co-developing models tailored to Korean partners' therapeutic indications and exploring how joint programs could be structured to deliver mutual scientific and commercial value.
British Columbia
Our goal is to connect with Korean life sciences and MedTech (medical device) companies and explore potential business and strategic partnerships. We are particularly interested in companies who benefit from our medical affairs consulting services as well as our connections and ability to build partnership in areas of commercialization, market entry, and business development. We believe Exquisite Biomedical Consulting is a valuable consulting firm who can support Korean companies expand into Canada and the North American market.
Alberta
Galena Wellness aims to establish strategic partnerships in South Korea with hospitals, universities, schools, workplace-wellness organizations, and community mental-health providers. Our objective is to develop and evaluate culturally adapted pilot programs using HeartMath-based HRV biofeedback and nervous-system self-regulation education to support stress management, emotional regulation, resilience, sleep, and early intervention. We are also seeking research, clinical-validation, implementation, and market-entry partners for the responsible future introduction of neurofeedback and photobiomodulation technologies.
Quebec
Our objective is to license our vaccine development technologies and supply our products to Korean vaccine developers. We target companies developing adjuvanted subunit vaccines, glycoconjugate programs, and adjuvant-combination studies in infectious diseases and cancer.
Quebec
To help identify potential partnerships with Korean biotech and pharmaceutical companies while highlighting Canada’s capabilities in vaccine development and laboratory services. Our key objectives are to foster new research collaborations and find clinical development opportunities that can contribute to growth within Canada’s life sciences ecosystem.
Ontario
JN Nova Pharma is a Canadian biotechnology company developing a proprietary platform technology to address multiple high-value unmet medical needs, including acute respiratory distress syndrome (ARDS), Idiopathic Pulmonary Fibrosis (IPF), Acute Kidney Injury (AKI). Our platform technology collectively targets global market opportunities exceeding $40 billion. We are interested in identifying co-development partners and clinical centers in Korea to conduct the clinicals studies in 2027.
British Columbia
Promote British Columbia's life sciences ecosystem to Korean pharmaceutical companies, investors, and innovation partners. Attract foreign direct investment (FDI) into British Columbia by showcasing the province's strengths in therapeutics, medtech, digital health, and AI-enabled drug discovery. Develop strategic partnerships with Korean pharmaceutical companies, research institutes, hospitals, and innovation clusters to support licensing, co-development, clinical trials, and commercialization.
Quebec
1. Pharmaceutical and biotech partnerships. 2. Investment. Meet strategic and financial investors with an interest in AI-enabled life sciences tooling, to support our Asia-Pacific expansion alongside LINEARIS Japan K.K. 3. Key opinion leaders in metabolomics. Establish direct relationships with Korean leaders in metabolomics and mass spectrometry, both to validate our platform in Korean clinical settings and to build the scientific advisory relationships that underpin adoption.
I am looking to deepen my understanding of the local health ecosystem by connecting with key stakeholders and initiating discussions. By engaging with healthcare providers, academic institutions, industry leaders, and community organizations, I hope to gain valuable insights into regional health priorities and identify shared areas of interest. My goal is to build strong, cross-disciplinary relationships that can serve as the foundation for impactful, collaborative research initiatives that address pressing health challenges.
Quebec
As an Economic Development Organization, our objective for this conference is to demonstrate to international companies the strategic advantage of opening a subsidiary in Greater Montreal, thanks to the attractiveness of our region. Since Montréal International is a non-profit organization, our services are free and confidential.
· Strategic partnerships and collaboration Build relationships across the Canadian and Korean ecosystems, including industry groups, funding agencies, and SMEs. · Technology development and commercialization Support research collaborations, licensing, fee-for-service activities, and connections between Canadian and Korean biologics companies. · Priority technology areas Focus on biologics development and biomanufacturing for vaccines and therapeutics, alongside enabling technologies such as microfluidics, lab-on-chip, organ-on-chip, bioanalytical devices, and biomedical data intelligence.
Possibility Neurotechnologies is commercializing Think2Switch™—a mobile, brain-computer interface platform enabling people with limited mobility to control technology using brain activity. We are seeking Korean partners for hardware integration, enterprise distribution, clinical validation, and joint R&D, with particular interest in rehabilitation robotics, connected technologies, digital health, and EEG hardware. We are also open to strategic investment discussions as part of our current Seed raise.
Ontario
Meet investors. Meet pharma R&D partners (peptide design, CNS delivery, oncology). Meet Korean breast cancer clinicians/centers.
British Columbia
Hospital system research, clinical trial, RWE, technology commercialization, joint R&D Pre-clinical, Phase I Clinical Trial, Licensing-Out (L/O), R&D CDMO (e.g., point of care manufacturing platform) Sequencing & library-prep reagents Molecular-Dx assay platforms/Diagnostic kits
Ontario
Pulse Infoframe empowers biopharma, healthcare providers, and patient advocacy groups to accelerate evidence generation for oncology, rare diseases, and complex conditions. Our cloud-based healthie™ platform seamlessly integrates and harmonizes diverse real-world data to support high-value patient registries, natural history studies, and external control arms. By converting fragmented health data into regulatory-ready insights, we help global partners streamline decision-making and speed access to life-saving therapies.
British Columbia
We aim to attract use-case adoption for our technology in Korea, with the system installed at KPBMA as a demonstration site. We are also interested in scoping technical talent for on-site operation and advancement of our Self-Driving Lab platform
1. Seeking clients for infectious disease contract research in BSL2, 3 and 4 and biologics contract development and manufacturing Seeking licensees for our human and animal health vaccine technologies 3. To create new partnerships/collaborations in infectious disease research and vaccine development
British Columbia
Partnership with Korean biotechs developing innovative small molecule (ADC payloads, TPD's, PROTACS, etc.) therapeutics using our Enki generative AI platform for drug discovery to create novel medicines across disease areas.
